CASR and neoplasm: In our previous clinical studies, we demonstrated a different CaSR level expression (score 0-4) in human primary breast cancers [38], in keeping with other clinical studies that further correlated the different expression level of CaSRs to the tumour proliferation and, in turn, to high risk of bone metastases [37].